Marta Guasch-Ferré1,2,3, José L Santos4, Miguel A Martínez-González1,5,6, Clary B Clish7, Cristina Razquin5,6, Dong Wang1, Liming Liang8, Jun Li1, Courtney Dennis7, Dolores Corella6,9, Carlos Muñoz-Bravo10, Dora Romaguera6,11, Ramón Estruch6,12, José Manuel Santos-Lozano6,13, Olga Castañer6,14, Angel Alonso-Gómez6,15, Luis Serra-Majem6,16, Emilio Ros6,17, Sílvia Canudas2,6, Eva M Asensio9, Montserrat Fitó6,14, Kerry Pierce7, J Alfredo Martínez6,18, Jordi Salas-Salvadó2,6, Estefanía Toledo5,6, Frank B Hu1,3, Miguel Ruiz-Canela5,6. 1. Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA, USA. 2. Human Nutrition Unit, Faculty of Medicine and Health Sciences, Pere Virgili Health Research Institute, Rovira i Virgili University, Reus, Spain. 3. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 4. Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. 5. Department of Preventive Medicine and Public Health, IdiSNA (Health Research Institute of Navarra), University of Navarra, Pamplona, Spain. 6. The Spanish Biomedical Research Center in Physiopathology of Obesity and Nutrition, Health Institute Carlos III, Madrid, Spain. 7. Broad Institute of MIT and Harvard University, Cambridge, MA, USA. 8. Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA. 9. Department of Preventive Medicine, University of Valencia, Valencia, Spain. 10. Department of Public Health and Psychiatry, University of Málaga, Málaga, Spain. 11. Health Research Institute of the Balearic Islands (IdISBa), University Hospital Son Espases, Mallorca, Spain. 12. Department of Internal Medicine, Department of Endocrinology and Nutrition Biomedical Research Institute August Pi Sunyer (IDI-BAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain. 13. Department of Family Medicine, Primary Care Division of Sevilla, San Pablo Health Center, Sevilla, Spain. 14. Cardiovascular and Nutrition Research Group, Hospital del Mar Research Institute (IMIM), Barcelona, Spain. 15. Bioaraba Health Research Institute; Osakidetza Baseque Health Service, Araba University Hospital; Unibersity of the Basque Country UPV/EHU; Vitoria-Gasteiz, Spain. 16. Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria and Service of Preventive Medicine, Complejo Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canary Health Service, Las Palmas de Gran Canaria, Spain. 17. Lipid Clinic, Department of Endocrinology and Nutrition Biomedical Research Institute August Pi Sunyer (IDI-BAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain. 18. Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, IMDEA Food, Madrid, Spain.
Abstract
BACKGROUND:Glycolysis/gluconeogenesis and tricarboxylic acid (TCA) cycle metabolites have been associated with type 2 diabetes (T2D). However, the associations of these metabolites with T2D incidence and the potential effect of dietary interventions remain unclear. OBJECTIVES: We aimed to evaluate the association of baseline and 1-y changes in glycolysis/gluconeogenesis and TCA cycle metabolites with insulin resistance and T2D incidence, and the potential modifying effect of Mediterranean diet (MedDiet) interventions. METHODS: We included 251 incident T2D cases and 638 noncases in a nested case-cohort study within the PREDIMED Study during median follow-up of 3.8 y. Participants were allocated to MedDiet + extra-virgin olive oil, MedDiet + nuts, or control diet. Plasma metabolites were measured using a targeted approach by LC-tandem MS. We tested the associations of baseline and 1-y changes in glycolysis/gluconeogenesis and TCA cycle metabolites with subsequent T2D risk using weighted Cox regression models and adjusting for potential confounders. We designed a weighted score combining all these metabolites and applying the leave-one-out cross-validation approach. RESULTS:Baseline circulating concentrations of hexose monophosphate, pyruvate, lactate, alanine, glycerol-3 phosphate, and isocitrate were significantly associated with higher T2D risk (17-44% higher risk for each 1-SD increment). The weighted score including all metabolites was associated with a 30% (95% CI: 1.12, 1.51) higher relative risk of T2D for each 1-SD increment. Baseline lactate and alanine were associated with baseline and 1-y changes of homeostasis model assessment of insulin resistance. One-year increases in most metabolites and in the weighted score were associated with higher relative risk of T2D after 1 y of follow-up. Lower risks were observed in the MedDiet groups than in the control group although no significant interactions were found after adjusting for multiple comparisons. CONCLUSIONS: We identified a panel of glycolysis/gluconeogenesis-related metabolites that was significantly associated with T2D risk in a Mediterranean population at high cardiovascular disease risk. A MedDiet could counteract the detrimental effects of these metabolites.This trial was registered at controlled-trials.com as ISRCTN35739639.
RCT Entities:
BACKGROUND: Glycolysis/gluconeogenesis and tricarboxylic acid (TCA) cycle metabolites have been associated with type 2 diabetes (T2D). However, the associations of these metabolites with T2D incidence and the potential effect of dietary interventions remain unclear. OBJECTIVES: We aimed to evaluate the association of baseline and 1-y changes in glycolysis/gluconeogenesis and TCA cycle metabolites with insulin resistance and T2D incidence, and the potential modifying effect of Mediterranean diet (MedDiet) interventions. METHODS: We included 251 incident T2D cases and 638 noncases in a nested case-cohort study within the PREDIMED Study during median follow-up of 3.8 y. Participants were allocated to MedDiet + extra-virgin olive oil, MedDiet + nuts, or control diet. Plasma metabolites were measured using a targeted approach by LC-tandem MS. We tested the associations of baseline and 1-y changes in glycolysis/gluconeogenesis and TCA cycle metabolites with subsequent T2D risk using weighted Cox regression models and adjusting for potential confounders. We designed a weighted score combining all these metabolites and applying the leave-one-out cross-validation approach. RESULTS: Baseline circulating concentrations of hexose monophosphate, pyruvate, lactate, alanine, glycerol-3 phosphate, and isocitrate were significantly associated with higher T2D risk (17-44% higher risk for each 1-SD increment). The weighted score including all metabolites was associated with a 30% (95% CI: 1.12, 1.51) higher relative risk of T2D for each 1-SD increment. Baseline lactate and alanine were associated with baseline and 1-y changes of homeostasis model assessment of insulin resistance. One-year increases in most metabolites and in the weighted score were associated with higher relative risk of T2D after 1 y of follow-up. Lower risks were observed in the MedDiet groups than in the control group although no significant interactions were found after adjusting for multiple comparisons. CONCLUSIONS: We identified a panel of glycolysis/gluconeogenesis-related metabolites that was significantly associated with T2D risk in a Mediterranean population at high cardiovascular disease risk. A MedDiet could counteract the detrimental effects of these metabolites.This trial was registered at controlled-trials.com as ISRCTN35739639.
Authors: Miguel Ángel Martínez-González; Dolores Corella; Jordi Salas-Salvadó; Emilio Ros; María Isabel Covas; Miquel Fiol; Julia Wärnberg; Fernando Arós; Valentina Ruíz-Gutiérrez; Rosa María Lamuela-Raventós; Jose Lapetra; Miguel Ángel Muñoz; José Alfredo Martínez; Guillermo Sáez; Lluis Serra-Majem; Xavier Pintó; María Teresa Mitjavila; Josep Antoni Tur; María Del Puy Portillo; Ramón Estruch Journal: Int J Epidemiol Date: 2010-12-20 Impact factor: 7.196
Authors: Jordi Merino; Aaron Leong; Ching-Ti Liu; Bianca Porneala; Geoffrey A Walford; Marcin von Grotthuss; Thomas J Wang; Jason Flannick; Josée Dupuis; Daniel Levy; Robert E Gerszten; Jose C Florez; James B Meigs Journal: Diabetologia Date: 2018-04-06 Impact factor: 10.122
Authors: Dagmar Drogan; Warwick B Dunn; Wanchang Lin; Brian Buijsse; Matthias B Schulze; Claudia Langenberg; Marie Brown; Anna Floegel; Stefan Dietrich; Olov Rolandsson; David C Wedge; Royston Goodacre; Nita G Forouhi; Stephen J Sharp; Joachim Spranger; Nick J Wareham; Heiner Boeing Journal: Clin Chem Date: 2014-12-18 Impact factor: 8.327
Authors: Carmen Marín; Elena M Yubero-Serrano; José López-Miranda; Francisco Pérez-Jiménez Journal: Int J Mol Sci Date: 2013-04-24 Impact factor: 5.923
Authors: Oded Shaham; Ru Wei; Thomas J Wang; Catherine Ricciardi; Gregory D Lewis; Ramachandran S Vasan; Steven A Carr; Ravi Thadhani; Robert E Gerszten; Vamsi K Mootha Journal: Mol Syst Biol Date: 2008-08-05 Impact factor: 11.429
Authors: Inken Padberg; Erik Peter; Sandra González-Maldonado; Henning Witt; Matthias Mueller; Tanja Weis; Bianca Bethan; Volker Liebenberg; Jan Wiemer; Hugo A Katus; Dietrich Rein; Philipp Schatz Journal: PLoS One Date: 2014-01-17 Impact factor: 3.240
Authors: Courtney J Smith; Nasa Sinnott-Armstrong; Anna Cichońska; Heli Julkunen; Eric B Fauman; Peter Würtz; Jonathan K Pritchard Journal: Elife Date: 2022-09-08 Impact factor: 8.713
Authors: Jakub Morze; Clemens Wittenbecher; Lukas Schwingshackl; Anna Danielewicz; Andrzej Rynkiewicz; Frank B Hu; Marta Guasch-Ferré Journal: Diabetes Care Date: 2022-04-01 Impact factor: 17.152
Authors: Nerea Becerra-Tomás; Miguel Ruiz-Canela; Pablo Hernández-Alonso; Mònica Bulló; Jun Li; Marta Guasch-Ferré; Estefanía Toledo; Clary B Clish; Ramon Estruch; Emilio Ros; Montserrat Fitó; Chih-Hao Lee; Kerry Pierce; Fernando Arós; Lluís Serra-Majem; Liming Liang; Cristina Razquin; Enrique Gómez-Gracia; Miguel A Martínez-González; Frank B Hu; Dolores Corella; Jordi Salas-Salvadó Journal: Metabolites Date: 2021-05-11